Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

159.88 -3.09 (-1.90%)
Streaming Delayed Price Updated: 12:58 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Novo Nordisk Earnings Conference Call Is Coming Up, Here's What You Need To Know
Novo Nordisk (NYSE:NVO) will host a conference call at 07:00 AM ET on August 4, 2022, to discuss Q2 2022 earnings results. How to Attend Novo Nordisk (NVO) Conference Call Follow this link to access... 
Via Benzinga
Novo Nordisk Once-Weekly Insulin Hits Primary Goals In In Two Phase 3 Trials
 
Via Benzinga
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could... 
Via FinancialNewsMedia
Exposures COVID-19 Product Safety
Keep AbbVie Stock On Your Watch List Ahead Of Earnings
Looking for stocks setting up in a base ahead of their next earnings report, here's one that fits the bill: AbbVie stock. 
Via Investor's Business Daily
Rhythm Has Tripled In A Week And Quintupled Since May — Here's Why
The company looks to take on behemoths Novo Nordisk and Eli Lilly in obesity drugs. 
Via Investor's Business Daily
With New Phase 3 Data From Its Hemophilia Study, Novo Nordisk Plots Route To FDA
 
Via Benzinga
Novo Nordisk's Mim8 Shows Potential As Once Monthly Treatment For Hemophilia A
 
Via Benzinga
$100 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 3.6% on an annualized basis producing an average annual return of 14.41%. Currently, Novo Nordisk has a market... 
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Is AbbVie Stock A Buy As Humira Biosimilar Rivals Loom?
Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.? Is AbbVie stock a buy today 
Via Investor's Business Daily
Here's How Much $1000 Invested In Novo Nordisk 5 Years Ago Would Be Worth Today
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 21.31%. Currently, Novo Nordisk has a market... 
Via Benzinga
Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022
Upgrades 
Via Benzinga
ESG Investing: 7 Profitable Stock Picks for the Socially Responsible
These seven stocks are the best choices to buy in June for people who are interested in jumping into ESG investing. 
Via InvestorPlace
If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 3.35% on an annualized basis producing an average annual return of 14.11%. Currently, Novo Nordisk has a market... 
Via Benzinga
As Health Problems Mount Patients Welcome New Treatments
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,... 
Via FinancialNewsMedia
5 Cash-Cow Stocks to Buy for a Turbulent Market
These are five of the best cash-cow stocks and ETFs to buy that could help grow your investment portfolio in the second half of 2022 
Via InvestorPlace
We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit
The conversation around obesity is changing. Two diabetes drug makers are at the forefront. 
Via Investor's Business Daily
Eli Lilly Presents New Analyses On Tirzepatide Injection For Type 2 Diabetes
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street
Pre-open movers 
Via Benzinga
Eli Lilly Flirts With Buy Point On A 'Flawless' Update For Its Diabetes-Turned-Obesity Drug
Eli Lilly is hoping to pivot its diabetes drug into obesity treatment. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2022
Upgrades 
Via Benzinga
Revolutionary Heart Therapy Offers Hope to Patients and Investors Alike
Palm Beach, FL – May 31, 2022 – FinancialNewsMedia.com News Commentary – Diabetes is a chronic health condition that occurs when your body’s blood glucose, also called blood sugar, is too high. Blood... 
Via FinancialNewsMedia
The 7 Best Long-Term Stocks to Buy and Hold Until 2032
Markets are shaky right now. But these seven best long-term stocks to buy and hold should work in just about any economic environment. 
Via InvestorPlace
Best Stock To Buy Now: Thursday, 25 May 2022
With the market going through its worst phase recently, it’s an excellent time to take stock of your investments and 
Via Best Stocks
Topics Economy Supply Chain
Exposures Economy Supply Chain
Top-Rated Eli Lilly Nears Breakout After FDA Approves Its Next Potential Blockbuster
The Food and Drug Administration approved an Eli Lilly diabetes drug it described as "novel," prodding LLY stock closer to a breakout. 
Via Investor's Business Daily
7 Profitable Places to Hide Your Money During a Bear Market
With an imminent bear market on the horizon, investors are searching for alternative investment paths for diversification. 
Via InvestorPlace
Eli Lilly, Novo Nordisk, Sanofi Accused Of Artificially Raising Insulin Prices
Arkansas has accused Eli Lilly And Co (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Sanofi SA (NASDAQ: SNY), and three of the largest pharmacy benefit... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.